10-K/A: Lisata Therapeutics Files Amended Annual Report

Lisata Therapeutics, Inc. has filed an amendment to its 2025 Form 10-K to include previously omitted Part III information regarding corporate governance, executive compensation, and security ownership.

Summary

• This filing is an amendment (Amendment No. 1) to Lisata Therapeutics, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
• The amendment is solely to include information for Part III of Form 10-K, specifically Items 10 (Directors, Executive Officers and Corporate Governance), 11 (Executive Compensation), 12 (Security Ownership), 13 (Certain Relationships and Related Transactions), and 14 (Principal Accounting Fees and Services).
• This amendment does not update or modify disclosures from the original filing dated March 12, 2026, except for the inclusion of the specified Part III information.
• The company is also filing updated certifications under Section 302 of the Sarbanes-Oxley Act.
• The aggregate market value of the Registrant's common stock held by non-affiliates was approximately $23.6 million as of June 30, 2025.
• As of April 28, 2026, there were 9,106,391 shares of common stock outstanding.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a procedural amendment to a previous annual report and does not introduce new financial or operational information, but rather corrects an omission in disclosure.

Positives

• The company has a well-structured board with independent directors, with a clear separation between the Chairman and CEO roles.
• All directors attended 100% of the board and committee meetings they were assigned to, with only minor exceptions.
• The company has adopted a code of ethics for its directors, officers, and employees.
• The company has an Insider Trading Policy in place to prevent violations and avoid the appearance of improper conduct.
• The company has a Stock Ownership Policy to align executive interests with stockholders, with executives making appropriate progress towards guidelines.
• The company has an Incentive Compensation Recoupment Policy to address serious misconduct by executives.

Negatives

• The filing is an amendment, indicating an omission in the original filing, which could suggest a procedural oversight.
• The company does not have a formal diversity policy for director nominations, although it believes its current board represents a diverse collection of skills.
• The company has not adopted an insider trading policy governing the purchase, sale, or disposition of its securities by the Company itself, though the Board approves such transactions on a case-by-case basis.

Risks

• The company's ability to obtain sufficient capital or strategic business arrangements to fund operations and expansion plans.
• The company's ability to continue as a going concern.
• Scientific, regulatory, and medical developments beyond the company's control.
• The company's ability to obtain and maintain appropriate governmental licenses, accreditations, or certifications.
• The potential for patent applications to not result in issued patents or for the company to infringe upon third-party patents.
• The results of development activities and the ability to complete clinical trials in accordance with estimated timelines.
• The impact of future public health crises on the company's business, clinical trials, and financial condition.

Future Outlook

The filing itself is an amendment to a previous annual report and does not contain new forward-looking statements or guidance. However, the original filing (referenced) likely contained forward-looking statements related to the company's operations, product development, and financial expectations, subject to the risks outlined in the document.

Management Comments

• The company believes that the separation of the Chairman and Chief Executive Officer roles enhances good corporate governance principles through reduction of conflicts of interest and greater board independence.
• The Nominating and Governance Committee believes the board represents a collection of individuals with a variety of complementary skills which, as a group, constitute the appropriate skills and experience to oversee Lisata's business.
• The company believes that a diversity of viewpoints and practical experiences can enhance the effectiveness of the Lisata Board.

Industry Context

StockSavvy.ai notes that this filing is a procedural amendment for a biotechnology company, focusing on corporate governance and executive compensation disclosures. Such amendments are common to ensure all required disclosures are complete and accurate, but do not typically signal new operational or financial developments.

Corporate Governance

Related Party Transactions

• During the fiscal year ended December 31, 2025, the company did not engage in any related party transactions.

Stakeholder Impact

• Shareholders: The amendment clarifies corporate governance and executive compensation, providing transparency. The stock ownership policy aims to align executive and shareholder interests.
• Employees: Executive compensation details are disclosed, and the insider trading policy applies to all personnel.
• Directors and Officers: Detailed information on their roles, compensation, and stock ownership is provided. They are subject to governance policies and stock ownership guidelines.

Next Steps

• The company will continue to operate under its established corporate governance structure.
• Executive compensation and director compensation will continue to be determined and overseen by the Compensation Committee.
• The company will continue to pursue its business objectives as outlined in its previous filings.

Key Dates

Keywords

Lisata Therapeutics, SEC Filing, 10-K Amendment, Corporate Governance, Executive Compensation, Directors, Officers, Stock Ownership, Financial Reporting, Biotechnology